Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Home
/
update
/
details

Roche Expands Digital Pathology Platform to Enhance AI-Driven Cancer Diagnostics

NextEdge Admin

10 Sep 2024

1 min 42 sec

Roche has expanded its digital pathology open environment by integrating over 20 advanced AI algorithms from eight new collaborators, aimed at enhancing cancer research and diagnosis. This integration, powered by Roche’s navify® Digital Pathology software, provides pathologists and scientists easy access to cutting-edge AI tools, supporting precision medicine and targeted treatments.

The new collaborations include Deep Bio for prostate cancer detection, DiaDeep for breast cancer biomarkers, Lunit for lung cancer TPS analysis, Mindpeak for various cancer biomarkers, Owkin for microsatellite stability screening in colorectal cancer, Qritive for prostate cancer and metastasis analysis, Sonrai Analytics for MSI status in colorectal cancer, and Stratipath for breast cancer risk profiling.

Jill German, Head of Pathology Lab at Roche Diagnostics, highlighted the goal of transforming cancer research, diagnostics, and treatment through AI. Roche's end-to-end digital pathology solutions integrate AI-driven algorithms to deliver reliable, high-quality results, advancing personalized healthcare. As immunotherapy accelerates, Roche is moving AI tools from research to routine clinical practice, reaffirming its commitment to innovation and improved patient outcomes in cancer care.